Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
It may improve immune response and reduce signs of premature ageing
Over 84 weeks: CagriSema achieved a 20.2% mean weight reduction Tirzepatide delivered a 23.6% mean weight reduction In this head-to-head comparison, CagriSema did not demonstrate equivalence to tirzepatide in terms of weight loss efficacy
Dulaglutide (Trulicity) Dulaglitide is a once-weekly GLP-1 agonist that is FDA-approved for promoting glycemic control in patients with type 2 diabetes
Curr Opin Pharmacol 2007
Drug Design, Development and Therapy 9:2485-2499
US$ 25.66
US$ 29.67
US$ 25.10
